-
-
-
-
-
-
-
Nurix Therapeutics, Inc. (NRIX) Tops Q4 EPS by 10c
-
-
-
-
-
-
-
Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
Nurix Therapeutics, Inc. (NRIX) Misses Q4 EPS by 7c
-
-
-
-
-
-
-
Nurix Therapeutics, Inc. (NRIX) Misses Q2 EPS by 8c
-
-
-
-
-
-
-
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
-
-
-
-
-
-
-
Nurix (NRIX) Opportunistically Strengthened Balance Sheet Ahead of Catalysts, PT to $37 - Stifel
-
1,197,523 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

